Genmab A/S to acquire ProfoundBio, Inc. to broaden and strengthen its oncology portfolio
04/03/24, 5:44 AM
Location
copenhagen
woodinvilleIndustry
therapeutics
biotechnology
health care
biotechnology
Genmab A/S (Nasdaq: GMAB) and ProfoundBio, Inc. have entered into a definitive agreement for an all-cash transaction valued at USD 1.8 billion. The acquisition will further broaden Genmab’s mid- to late-stage clinical pipeline and strengthen its suite of proprietary technology platforms. Genmab's acquisition of ProfoundBio's next-generation ADCs and ADC technologies aims to create new opportunities in the treatment of cancer, particularly in gynecologic oncology and solid tumors.
Company Info
Location
Copenhagen, Capital Region Of Denmark, Denmark
Company info
Genmab A/S is a publicly traded biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. It has a validated suite of proprietary technology platforms and a mid- to late-stage clinical pipeline. The company is committed to impacting the lives of patients through innovative antibody medicines.